Trial · NCT00130286

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286, Phase 1, Phase 2, Completed, Weill Medical College of Cornell University; results first posted 2014-02-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance. Trials, record NCT00130286. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00130286

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
NCT number: NCT00130286
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 77 participants, actual
Lead sponsor: Weill Medical College of Cornell University
Conditions: HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions: Rosiglitazone, Recombinant human growth hormone + rosiglitazone
First posted: 2005-08-15
Last updated: 2014-02-13
Results first posted: 2014-02-13

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Insulin Sensitivity	12 weeks	Change in insulin sensitivity value from baseline to week 12 by frequently sampled intravenous glucose tolerance test This assessment was only conducted at baseline and week 12; therefore the change reflects the difference between these two time points.
Secondary	Change in Visceral Adipose Tissue Volume	12 weeks	Change in visceral adipose tissue volume from baseline to week 12 measured by whole body MRI Data are presented only for subjects who had MRI scans done at both time points.
Secondary	Change in Subcutaneous Adipose Tissue Volume	12 weeks	Change in subcutaneous adipose tissue volume from baseline to week 12 by whole body MRI Data are presented only for subjects who had MRI scans done at both time points.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change in Insulin Sensitivity	12 weeks	uU10^-4min*ml^-1	MEDIAN
SECONDARY	Change in Visceral Adipose Tissue Volume	12 weeks	L	MEAN
SECONDARY	Change in Subcutaneous Adipose Tissue Volume	12 weeks	L	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Insulin Sensitivity	rhGH + Rosi	0.20	Inter-Quartile Range -0.37 to 1.00	uU10^-4min*ml^-1
Change in Insulin Sensitivity	rhGH Placebo + Rosi	1.44	Inter-Quartile Range 0.68 to 2.59	uU10^-4min*ml^-1
Change in Insulin Sensitivity	rhGH + Rosi Placebo	-0.63	Inter-Quartile Range -1.03 to 0.11	uU10^-4min*ml^-1
Change in Insulin Sensitivity	Double Placebo	0.14	Inter-Quartile Range -0.41 to 1.21	uU10^-4min*ml^-1
Change in Visceral Adipose Tissue Volume	rhGH + Rosi	-1.13	Standard Deviation 1.41	L
Change in Visceral Adipose Tissue Volume	rhGH Placebo + Rosi	-0.19	Standard Deviation 0.69	L
Change in Visceral Adipose Tissue Volume	rhGH + Rosi Placebo	-1.15	Standard Deviation 0.81	L
Change in Visceral Adipose Tissue Volume	Double Placebo	-0.04	Standard Deviation 0.9	L
Change in Subcutaneous Adipose Tissue Volume	rhGH + Rosi	-0.11	Standard Deviation 3.33	L
Change in Subcutaneous Adipose Tissue Volume	rhGH Placebo + Rosi	0.74	Standard Deviation 1.86	L

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	rhGH + Rosi	22
Overall Study	STARTED	rhGH Placebo + Rosi	19
Overall Study	STARTED	rhGH + Rosi Placebo	17
Overall Study	STARTED	Double Placebo	19
Overall Study	COMPLETED	rhGH + Rosi	22
Overall Study	COMPLETED	rhGH Placebo + Rosi	16
Overall Study	COMPLETED	rhGH + Rosi Placebo	13
Overall Study	COMPLETED	Double Placebo	17
Overall Study	NOT COMPLETED	rhGH + Rosi	0
Overall Study	NOT COMPLETED	rhGH Placebo + Rosi	3

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events96

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Fever	General disorders	rhGH + Rosi	0	22
other	Fever	General disorders	rhGH Placebo + Rosi	1	18
other	Fever	General disorders	rhGH + Rosi Placebo	1	15
other	Fever	General disorders	Double Placebo	2	17
other	Fatigue	General disorders	rhGH + Rosi	7	22
other	Fatigue	General disorders	rhGH Placebo + Rosi	6	18
other	Fatigue	General disorders	rhGH + Rosi Placebo	5	15
other	Fatigue	General disorders	Double Placebo	5	17
other	Weight gain	General disorders	rhGH + Rosi	1	22
other	Weight gain	General disorders	rhGH Placebo + Rosi	0	18

1 to 10 of 96Source ClinicalTrials.gov

See all 96 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	rhGH + Rosi
Total, all-cause mortality	rhGH Placebo + Rosi
Total, all-cause mortality	rhGH + Rosi Placebo
Total, all-cause mortality	Double Placebo
Total, other adverse events	rhGH + Rosi	17	22
Total, other adverse events	rhGH Placebo + Rosi	11	18
Total, other adverse events	rhGH + Rosi Placebo	14	15
Total, other adverse events	Double Placebo	9	17
Total, serious adverse events	rhGH + Rosi	1	22
Total, serious adverse events	rhGH Placebo + Rosi	1	19

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
23593417	RESULT	PubMed
25536669	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01DK065515	Growth Hormone and Rosiglitazone for Visceral Adoposity	GLESBY, MARSHALL J	WEILL MEDICAL COLL OF CORNELL UNIV	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES	2004 to 2007

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00130286

GET https://conductscience.org/api/trials/v1/NCT00130286/events?page=2

API reference For AI assistants